Comparative Pharmacology
Head-to-head clinical analysis: ISOETHARINE MESYLATE versus METAPROTERENOL SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISOETHARINE MESYLATE versus METAPROTERENOL SULFATE.
ISOETHARINE MESYLATE vs METAPROTERENOL SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-2 adrenergic receptor agonist; stimulates adenylate cyclase, increasing cAMP in bronchial smooth muscle, leading to bronchodilation.
Selective beta-2 adrenergic receptor agonist that activates adenylate cyclase, increasing intracellular cyclic AMP leading to bronchodilation and inhibition of mast cell mediator release.
Inhalation: 1-2 inhalations (0.34 mg per actuation) via metered-dose inhaler every 4-6 hours as needed; or 0.25-0.5 mL of 1% solution diluted in 2-3 mL of normal saline via nebulizer every 4-6 hours.
2.5 mg (0.25 mL of 1% solution) by nebulization every 6-8 hours. For oral, 20 mg every 6-8 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 2.5–5 hours in adults after inhalation; may be prolonged in patients with hepatic or renal impairment.
Terminal elimination half-life: 2-6 hours. Clinical context: Shorter half-life requires frequent dosing; prolongation in renal impairment.
Primarily renal excretion of unchanged drug and metabolites (sulfate and glucuronide conjugates); approximately 40-50% excreted renally as unchanged drug within 24 hours, with the remainder as metabolites. Biliary/fecal excretion is minimal (<5%).
Renal: 40-60% as unchanged drug and metabolites; biliary/fecal: ~40% as metabolites.
Category C
Category C
Beta-2 Adrenergic Agonist
Beta-2 Adrenergic Agonist